Notis McConarty Edward Has $924,000 Stake in Bristol-Myers Squibb Co (NYSE:BMY)

Notis McConarty Edward lowered its position in Bristol-Myers Squibb Co (NYSE:BMY) by 2.5% during the second quarter, according to its most recent filing with the SEC. The firm owned 20,361 shares of the biopharmaceutical company’s stock after selling 525 shares during the period. Notis McConarty Edward’s holdings in Bristol-Myers Squibb were worth $924,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Castle Rock Wealth Management LLC acquired a new position in shares of Bristol-Myers Squibb during the fourth quarter worth approximately $420,000. Dimensional Fund Advisors LP lifted its position in shares of Bristol-Myers Squibb by 0.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 4,012,753 shares of the biopharmaceutical company’s stock worth $208,561,000 after purchasing an additional 35,653 shares in the last quarter. Green Square Capital LLC lifted its holdings in Bristol-Myers Squibb by 7.4% in the fourth quarter. Green Square Capital LLC now owns 4,178 shares of the biopharmaceutical company’s stock valued at $217,000 after buying an additional 289 shares during the period. Suntrust Banks Inc. lifted its holdings in Bristol-Myers Squibb by 2.5% in the fourth quarter. Suntrust Banks Inc. now owns 553,321 shares of the biopharmaceutical company’s stock valued at $28,762,000 after buying an additional 13,536 shares during the period. Finally, Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp lifted its holdings in Bristol-Myers Squibb by 90.0% in the fourth quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp now owns 452,200 shares of the biopharmaceutical company’s stock valued at $23,505,000 after buying an additional 214,200 shares during the period. Hedge funds and other institutional investors own 77.71% of the company’s stock.

In related news, Director Theodore R. Samuels II bought 5,000 shares of the business’s stock in a transaction dated Thursday, May 16th. The stock was bought at an average price of $47.29 per share, for a total transaction of $236,450.00. Following the purchase, the director now owns 27,000 shares in the company, valued at approximately $1,276,830. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Robert J. Bertolini bought 11,000 shares of the business’s stock in a transaction dated Wednesday, July 31st. The shares were bought at an average price of $44.72 per share, with a total value of $491,920.00. Following the purchase, the director now owns 11,397 shares in the company, valued at approximately $509,673.84. The disclosure for this purchase can be found here. Company insiders own 0.13% of the company’s stock.

Shares of BMY stock traded down $0.75 during trading hours on Monday, hitting $45.24. 8,461,828 shares of the company were exchanged, compared to its average volume of 14,484,314. The company has a 50 day moving average of $45.66. The company has a quick ratio of 3.75, a current ratio of 3.88 and a debt-to-equity ratio of 1.51. Bristol-Myers Squibb Co has a 52 week low of $42.48 and a 52 week high of $63.69. The stock has a market cap of $74.57 billion, a P/E ratio of 11.37, a PEG ratio of 2.28 and a beta of 0.73.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, July 25th. The biopharmaceutical company reported $1.18 earnings per share for the quarter, beating analysts’ consensus estimates of $1.06 by $0.12. Bristol-Myers Squibb had a net margin of 26.14% and a return on equity of 47.63%. The business had revenue of $6.27 billion during the quarter, compared to the consensus estimate of $6.10 billion. During the same quarter last year, the firm earned $1.01 earnings per share. The firm’s revenue for the quarter was up 10.0% compared to the same quarter last year. As a group, sell-side analysts forecast that Bristol-Myers Squibb Co will post 4.26 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Thursday, August 1st. Stockholders of record on Friday, July 5th were paid a dividend of $0.41 per share. This represents a $1.64 dividend on an annualized basis and a dividend yield of 3.63%. The ex-dividend date of this dividend was Wednesday, July 3rd. Bristol-Myers Squibb’s dividend payout ratio is presently 41.21%.

Several equities analysts recently weighed in on BMY shares. JPMorgan Chase & Co. started coverage on shares of Bristol-Myers Squibb in a report on Friday, May 3rd. They issued an “overweight” rating and a $62.00 price objective on the stock. Argus lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $46.36 price objective on the stock. in a report on Monday, May 20th. Goldman Sachs Group started coverage on shares of Bristol-Myers Squibb in a report on Tuesday, May 28th. They issued a “buy” rating and a $54.00 price objective on the stock. Barclays upgraded shares of Bristol-Myers Squibb from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $53.00 to $55.00 in a report on Friday, May 3rd. Finally, Zacks Investment Research upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $54.00 price objective on the stock in a report on Tuesday, May 7th. One analyst has rated the stock with a sell rating, nine have given a hold rating and eight have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $55.45.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Recommended Story: The mechanics of the bid-ask spread in trading

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.